Document Detail

Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration.
MedLine Citation:
PMID:  17921260     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Buprenorphine is under investigation as a pharmacotherapeutic agent for treating opioid dependence in pregnant women. We hypothesized that there would be a relationship between the cumulative maternal dose of buprenorphine during pregnancy and the concentration of buprenorphine and norbuprenorphine in maternal and infant hair. METHODS: This study examined buprenorphine and norbuprenorphine concentrations in hair obtained from 9 buprenorphine-maintained pregnant women and 4 of their infants. Specimens were analyzed by liquid chromatography-tandem mass spectrometry with limits of quantification of 3.0 pg/mg. All maternal hair specimens were washed with methylene chloride before analysis, and when sufficient amounts of maternal hair were available, specimens also were analyzed without washing. Infant hair specimens were not washed. RESULTS: Buprenorphine concentrations were significantly greater in unwashed hair than washed hair (P = 0.031). Norbuprenorphine concentrations were significantly greater than buprenorphine concentrations in both maternal (P = 0.0097) and infant hair (P = 0.0033). There were statistically significant associations between the cumulative maternal dose of buprenorphine administered and the concentrations of buprenorphine (washed, P <0.0001; unwashed, P = 0.0004), norbuprenorphine (washed, P <0.0001; unwashed, P = 0.0005), and buprenorphine plus norbuprenorphine (washed, P <0.0001; unwashed, P = 0.0005) for both washed and unwashed maternal hair specimens. There was a significant positive association between concentrations of buprenorphine and norbuprenorphine in maternal hair (washed, P <0.0001; unwashed, P = 0.0003), a trend for this association in infant hair (P = 0.08), and an association between buprenorphine concentrations in maternal unwashed hair and infant hair (P = 0.0002). The buprenorphine:norbuprenorphine ratio increased in distal segments. CONCLUSION: Buprenorphine treatment during gestation provides an opportunity for monitoring drug disposition in maternal and fetal tissues under controlled conditions.
Robert S Goodwin; Diana G Wilkins; Olga Averin; Robin E Choo; Jennifer R Schroeder; Donald R Jasinski; Rolley E Johnson; Hendrée E Jones; Marilyn A Huestis
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural     Date:  2007-10-05
Journal Detail:
Title:  Clinical chemistry     Volume:  53     ISSN:  0009-9147     ISO Abbreviation:  Clin. Chem.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-02-12     Completed Date:  2008-03-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421549     Medline TA:  Clin Chem     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2136-43     Citation Subset:  IM    
Chemistry and Drug Metabolism Section, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Buprenorphine / analogs & derivatives*,  analysis,  pharmacokinetics,  therapeutic use
Chromatography, Liquid
Hair / chemistry*
Heroin Dependence / drug therapy,  metabolism*
Infant, Newborn
Pregnancy Complications / drug therapy,  metabolism*
Receptors, Opioid, kappa / antagonists & inhibitors
Receptors, Opioid, mu / agonists
Tandem Mass Spectrometry
Tissue Distribution
Grant Support
Reg. No./Substance:
0/Receptors, Opioid, kappa; 0/Receptors, Opioid, mu; 52485-79-7/Buprenorphine; 78715-23-8/norbuprenorphine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Modified form of the fibrinogen Bbeta chain (des-Gln Bbeta), a potential long-lived marker of pancre...
Next Document:  Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen ...